lled 301 individuals at 33 MS centers in the United States and Canada, recruited patients between 18 and 70 years old with a definite diagnosis of MS and some degree of walking disability. The study was open to people with all types of MS, including primary-progressive, secondary-progressive, relapsing-remitting and progressive-relapsing. Participants were permitted to remain on a stable regimen of their current medications, including interferons. Secondary endpoints for the trial included measurements of leg strength. Subjects were randomized to 14 weeks of treatment with Fampridine-SR (n=229) or placebo (n=72), a 3:1 ratio of drug to placebo.
In this study, adverse events were largely consistent with the safety profile observed in previous studies of Fampridine-SR in people with MS, including an increased risk of seizures that appears to be dose related. Following is a list of the most common adverse events reported in the study, with percentages representing the Fampridine-SR treatment group vs. the placebo group: falls (15.8 percent vs.15.3 percent), urinary tract infection (13.6 percent vs.13.9 percent), dizziness (8.3 percent vs. 5.6 percent), insomnia (8.3 percent vs. 4.2 percent), fatigue (6.1 percent vs. 2.8 percent), nausea (6.1 percent vs. 4.2 percent), upper respiratory tract infection (6.1 percent vs. 9.7 percent), asthenia (5.7 percent vs. 6.9 percent), back pain (5.7 percent vs. 0 percent), balance disorder (5.7 percent vs. 2.8 percent) and headache (5.7 percent vs. 5.6 percent).
Two serious adverse events that were judged potentially related to treatment and led to discontinuation were anxiety in one subject and a seizure in another subject that was observed during an occurrence of sepsis associated with a urinary tract infection. No deaths occurred during the study. One death was reported for a subject five weeks after the last on-drug study visit. This death occurred outside of the protocol tiPage: 1 2 3 4 5 Related biology news :1
Contact: Erica Wishner, Acorda Therapeutics
. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ2
. ESA announces 2007 award recipients3
. President Bush announces 2005 and 2006 Laureates of National Medals of Science and Technology4
. Conservation Leadership Program announces 2007 awardees5
. ACMG Foundation announces 2007-2008 Luminex/ACMGF award recipient6
. Revolutionary global environment fund announces $50M expansion7
. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID8
. Cell Press announces new partnership with the American Society of Human Genetics9
. ChemGenex announces publication confirming activity of Ceflatonin in T315I-Positive CML10
. Minister Lunn announces $39.6M for next phase of mountain pine beetle response11
. BioMed Central announces new interdisciplinary Biofuels Journal